-
Estimation of treatment policy estimands for continuous outcomes using off treatment sequential multiple imputation
Authors:
Thomas Drury,
Juan J Abellan,
Nicky Best,
Ian R. White
Abstract:
The estimands framework outlined in ICH E9 (R1) describes the components needed to precisely define the effects to be estimated in clinical trials, which includes how post-baseline "intercurrent" events (IEs) are to be handled. In late-stage clinical trials, it is common to handle intercurrent events like "treatment discontinuation" using the treatment policy strategy and target the treatment effe…
▽ More
The estimands framework outlined in ICH E9 (R1) describes the components needed to precisely define the effects to be estimated in clinical trials, which includes how post-baseline "intercurrent" events (IEs) are to be handled. In late-stage clinical trials, it is common to handle intercurrent events like "treatment discontinuation" using the treatment policy strategy and target the treatment effect on all outcomes regardless of treatment discontinuation. For continuous repeated measures, this type of effect is often estimated using all observed data before and after discontinuation using either a mixed model for repeated measures (MMRM) or multiple imputation (MI) to handle any missing data. In basic form, both of these estimation methods ignore treatment discontinuation in the analysis and therefore may be biased if there are differences in patient outcomes after treatment discontinuation compared to patients still assigned to treatment, and missing data being more common for patients who have discontinued treatment. We therefore propose and evaluate a set of MI models that can accommodate differences between outcomes before and after treatment discontinuation. The models are evaluated in the context of planning a phase 3 trial for a respiratory disease. We show that analyses ignoring treatment discontinuation can introduce substantial bias and can sometimes underestimate variability. We also show that some of the MI models proposed can successfully correct the bias but inevitably lead to increases in variance. We conclude that some of the proposed MI models are preferable to the traditional analysis ignoring treatment discontinuation, but the precise choice of MI model will likely depend on the trial design, disease of interest and amount of observed and missing data following treatment discontinuation.
△ Less
Submitted 25 August, 2023; v1 submitted 21 August, 2023;
originally announced August 2023.
-
Implementation and pratical aspects of quantitative decision-making in clinical drug development
Authors:
Juan J. Abellan,
Nicolas Bonnet,
Alex Carlton,
Paul Frewer,
Heiko Götte,
John-Philip Lawo,
Jesper Madsen,
Oliver Sailer,
Guido Thömmes,
Gaëlle Saint-Hilary
Abstract:
Quantitative decision-making (QDM) principles address the issues related to the map** of results to decisions, the synthesis of information and the quantification of uncertainty. Since the clinical drug development involves a succession of decisions to be made, QDM methods can be applied at various levels. At the study level, it can be used to properly design a study, and improve the decisions t…
▽ More
Quantitative decision-making (QDM) principles address the issues related to the map** of results to decisions, the synthesis of information and the quantification of uncertainty. Since the clinical drug development involves a succession of decisions to be made, QDM methods can be applied at various levels. At the study level, it can be used to properly design a study, and improve the decisions that are made either during the trial or at its end. Establishing decision criteria ahead of the study is essential here to address the need for speedy decisions, potentially in real time. At the project level, QDM can be used to inform decisions to continue, adapt or stop a drug development programme based on results from previous studies. At the portfolio level, QDM can be used to choose, prioritise and optimise the development portfolio, e.g. using the probability to reach market access or target sales within a predefined timeline. The increasing interest in QDM and its statistical nature led in 2017 to the development a cross-industry and academia Special Interest Group on QDM within the Society and the European Federation of Statisticians in the Pharmaceutical Industry (PSI and EFSPI). The activities of the group included discussing QDM examples, some published in the literature and some real anonymised ones covering several settings. While the methodologies, and to some extent the terminology, employed also varied depending on the context, discussions within the group distilled common principles to be considered when implementing QDM, particularly around the construction of QDM frameworks, assessment of operating characteristics and communication with the clinical team. The present manuscript presents those points to consider, ho** they can be helpful to statisticians interested in implementing QDM.
△ Less
Submitted 16 July, 2022;
originally announced July 2022.
-
Awareness and use of quantitative decision-making methods in pharmaceutical development
Authors:
Guido Thömmes,
Martin Oliver Sailer,
Nicolas Bonnet,
Alex Carlton,
Juan J. Abellan,
Veronique Robert
Abstract:
The pharmaceutical industry has experienced increasing costs and sustained high attrition rates in drug development over the last years. One proposal that addresses this challenge from a statistical perspective is the use of quantitative decision-making (QDM) methods to support a data-driven, objective appraisal of the evidence that forms the basis of decisions at different development levels. Gro…
▽ More
The pharmaceutical industry has experienced increasing costs and sustained high attrition rates in drug development over the last years. One proposal that addresses this challenge from a statistical perspective is the use of quantitative decision-making (QDM) methods to support a data-driven, objective appraisal of the evidence that forms the basis of decisions at different development levels. Growing awareness among statistical leaders in the industry has led to the creation of the European EFSPI/PSI special interest group (ESIG) on quantitative decision making to share experiences, collect best practices, and promote the use of QDM. In this paper, we introduce key components of QDM and present examples of QDM methods on trial, program, and portfolio level. The ESIG created a questionnaire to learn how and to what extent QDM methods are currently used in the different development phases. We present the main questionnaire findings, and we show where QDM is already used today but also where areas for future improvement can be identified. In particular, statisticians should increase their visibility, involvement, and leadership in cross-functional decision-making.
△ Less
Submitted 1 March, 2022;
originally announced March 2022.